![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Publisher: Adis International
ISSN: 1173-8324
Source: Inpharma, Vol.1, Iss.1222, 2000-01, pp. : 12-12
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
NSAIDs reduce risk of prostate cancer?
Inpharma, Vol. 1, Iss. 1335, 2002-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Do antiandrogens improve survival in prostate cancer?
Inpharma, Vol. 1, Iss. 1236, 2000-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Where to now with hormonal therapy in prostate cancer?
Inpharma, Vol. 1, Iss. 1239, 2000-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Bicalutamide: an alternative to castration in prostate cancer?
Inpharma, Vol. 1, Iss. 1554, 2006-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
COX-2 inhibitors: potential in prostate cancer?
Inpharma, Vol. 1, Iss. 1265, 2000-01 ,pp. :